Endometriosis, a chronic and often debilitating condition affecting approximately 10% of women and girls of reproductive age globally, remains one of the most significant challenges in modern gynecology. Recent research conducted by Nomi Health, a healthcare technology and payments company, has illuminated the profound financial and clinical consequences of the diagnostic delays that characterize this condition. By leveraging data from its Artemis analytics platform, Nomi Health identified that the period preceding a formal diagnosis of endometriosis is marked by high healthcare utilization, fragmented care across multiple specialties, and a significant economic burden on both patients and employers. The findings underscore a critical need for a paradigm shift in how the medical community identifies and manages women’s health conditions that extend beyond maternity care.
Understanding the Clinical Complexity of Endometriosis
Endometriosis is characterized by the growth of tissue similar to the lining of the uterus—the endometrium—in locations outside the uterine cavity. This tissue can be found on the ovaries, fallopian tubes, outer surface of the uterus, and even on the bladder, bowel, or rectum. Unlike the lining of the uterus, which is shed during menstruation, this misplaced tissue has no way to exit the body. This leads to internal bleeding, inflammation, and the formation of scar tissue or adhesions, which can cause organs to fuse together.
The symptoms of endometriosis are notoriously varied and often overlap with other medical conditions. While many associate the disease primarily with severe pelvic pain and dysmenorrhea (painful periods), it frequently manifests as chronic back pain, gastrointestinal distress, urinary issues, migraines, and profound fatigue. One of the most severe complications is infertility; the American Society for Reproductive Medicine estimates that endometriosis is present in up to 50% of women experiencing difficulty conceiving. Despite these severe manifestations, the condition is frequently dismissed by both society and medical professionals as "normal" menstrual discomfort, contributing to a systemic under-diagnosis.
The Diagnostic Odyssey: A Timeline of Delay
National data from organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the American Medical Association (AMA) indicate that the average time from the onset of symptoms to a definitive diagnosis of endometriosis ranges between four and eleven years. This "diagnostic odyssey" is a period of immense physical and psychological strain for patients.
The Nomi Health study tracked the medical journeys of women within a commercially insured population, specifically focusing on those who received their first observed diagnosis of endometriosis between 2023 and 2025. To capture the full scope of the pre-diagnosis phase, researchers analyzed medical and pharmacy claims for the 12 months immediately preceding the formal diagnosis. This methodology allowed for a quantifiable look at the "hidden" costs of the disease—spending that occurs while the healthcare system is still attempting to identify the root cause of a patient’s symptoms.
During this 12-month window, patients were found to be seeking care for a wide array of seemingly unrelated conditions. Researchers identified 15 to 20 "overlap" conditions frequently seen in undiagnosed endometriosis patients, including:
- Pelvic inflammatory disease (PID)
- Irritable bowel syndrome (IBS) and other inflammatory bowel issues
- Sciatica and chronic lower back pain
- Iron deficiency anemia resulting from heavy menstrual bleeding
- Chronic fatigue syndrome and clinical exhaustion
- Interstitial cystitis or recurring urinary tract infections
The research revealed that many women saw an average of four different medical specialists—ranging from gastroenterologists and orthopedists to rheumatologists and primary care providers—before their symptoms were correctly attributed to endometriosis.
The Economic Impact on Employers and the Healthcare System
The financial implications of these diagnostic gaps are substantial. Nomi Health’s analysis of its "book of business" data, which includes over 3,000 employer customers, found that for a single cohort of approximately 21,000 to 23,000 women, the healthcare spending on these 15 to 20 overlap conditions totaled nearly $37 million annually. Notably, this figure represents spending before the diagnosis was even made. It does not include the actual treatment for endometriosis itself, but rather the cost of managing its disparate symptoms under different clinical labels.
Per-patient spending was found to be approximately $1,800 per year during the pre-diagnosis phase for these specific conditions. However, once a formal diagnosis was reached and specialized care began, the annual cost of treatment—including surgery, hormone therapy, and pain management—typically rose to between $5,000 and $6,000 per member.
From an employer’s perspective, the costs extend beyond direct medical claims. The debilitating nature of endometriosis symptoms leads to significant "presenteeism" (working while impaired) and absenteeism. Women suffering from untreated endometriosis often require frequent sick leave, and the chronic nature of the pain can lead to long-term disability claims. Furthermore, the mental health burden associated with years of unexplained pain and medical dismissal is a significant factor. Nomi Health’s data showed a high rate of mental health comorbidities, such as anxiety and depression, among women in the pre-diagnosis cohort, further increasing the total cost of care.
Fragmentation and the Role of Data in Diagnosis
A primary driver of the diagnostic delay is the lack of integrated data and communication between medical providers. Dr. Rani Aravamudhan, Senior Medical Director at Nomi Health, highlights that the current healthcare system often operates in silos. A patient may visit a primary care provider for fatigue, a gastroenterologist for abdominal pain, and an orthopedist for back pain. Without a unified data view, these providers may not realize that these symptoms are part of a singular, systemic pathology.
The Artemis platform used in the Nomi Health study serves as a model for how data-driven decisions can bridge these gaps. By aggregating claims, lab data, and pharmacy records at the member level, stakeholders can identify patterns that are invisible in isolated clinical encounters. For example, the simultaneous presence of three or more of the "overlap" conditions identified in the study could serve as a clinical red flag, prompting earlier screening for endometriosis.
Evolving Clinical Guidelines and Future Outlook
In response to the long-standing issues surrounding endometriosis care, clinical guidelines are beginning to evolve. Traditionally, the "gold standard" for a definitive diagnosis has been laparoscopic surgery followed by a biopsy. However, the invasive nature of surgery and the associated costs have often caused providers to delay this step until all other possibilities are exhausted.
New recommendations from ACOG, the AMA, and various European health organizations are moving toward a "clinical diagnosis" model. This approach encourages providers to initiate treatment based on patient history, physical examination, and non-invasive imaging (such as specialized ultrasound or MRI) rather than waiting for surgical confirmation. By treating the condition as a presumptive diagnosis, clinicians can provide relief to patients years earlier, potentially slowing the progression of the disease and reducing long-term complications like infertility.
Furthermore, the healthcare industry is seeing a broader push to expand the definition of "women’s health." Historically, many employer-sponsored health plans and wellness programs have focused almost exclusively on maternity and reproductive health. While maternal health remains a priority, there is a growing realization that women’s health encompasses a wide range of chronic conditions that require specialized attention throughout a woman’s life, from adolescence through menopause.
Strategic Recommendations for Healthcare Stakeholders
The findings of the Nomi Health research suggest several actionable steps for various players in the healthcare ecosystem:
For Patients and Advocates
Self-advocacy is paramount. Women are encouraged to educate themselves about the symptoms of endometriosis and their own family history, as the condition has a strong hereditary component. When symptoms are dismissed by providers, seeking a second opinion from a specialist in minimally invasive gynecologic surgery (MIGS) or a dedicated endometriosis center is often necessary.
For Medical Providers
Clinicians must adopt a more holistic view of patient complaints. Chronic pelvic pain or severe menstrual symptoms should not be dismissed as "normal." Providers across different specialties—especially those in primary care, GI, and orthopedics—should be trained to recognize the extra-pelvic manifestations of endometriosis and maintain a low threshold for referral to a gynecologist.
For Employers and Payers
Health plan sponsors should evaluate their benefits packages to ensure they provide adequate coverage for specialized women’s health services. This includes access to multidisciplinary pain management, mental health support, and advanced imaging. Additionally, when selecting digital health or wellness vendors, employers should look for solutions that address chronic conditions like endometriosis and polycystic ovary syndrome (PCOS) in addition to standard maternity programs.
For Health Systems and Analysts
Investing in data interoperability is essential. When providers can see a comprehensive history of a patient’s visits across different specialties, they are much more likely to connect the dots and reach an accurate diagnosis. Predictive analytics and population health tools can be used to identify members at high risk for undiagnosed endometriosis, allowing for proactive intervention.
Conclusion
The gaps in endometriosis care represent a significant failure in the current healthcare landscape, resulting in years of unnecessary suffering for millions of women and billions of dollars in inefficient spending. However, the research provided by Nomi Health offers a roadmap for improvement. By utilizing data to identify clinical patterns, shortening the time to diagnosis through updated guidelines, and expanding the focus of women’s health benefits, the healthcare industry can move toward a more equitable and effective model of care. Addressing the "hidden" burden of endometriosis is not only a clinical necessity but an economic imperative for a healthy and productive society.
